Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503919-15-00

Acronym

I3Y-MC-JPEI

Enrollment

Registered

2023-11-30

Start date

2024-01-09

Completion date

2026-01-21

Last updated

2024-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Neoplasms

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026